Nanolek LLC announces personnel changes in the company's management. Evgeny Barinov has been appointed General Director of the biopharmaceutical holding since January 23, 2025. He will continue the company's development course aimed at strengthening its position in the market and expanding production capacities, and will focus on further improvement of the financial management and implementation of innovative digital technologies. Vladimir Nesterenko, who has held this position since 2023, will continue to work for the company as an advisor to General Director and will focus on the strategic development issues.
The personnel changes are part of the company's strategy aimed at significantly strengthening its market position and intensive development in line with the governmental policy of technological sovereignty. In 2023-2024, Nanolek focused on expanding its capacity, building interactions with partners, thus forming the foundation for organizing full-cycle production, as well as creating innovative drugs for the prevention and treatment of socially significant diseases.
In the current year, Nanolek will continue the development course outlined in previous periods. The company's plans include further enhancement of production, development of innovations, as well as optimization of operational and other processes through the introduction of new modern technologies, primarily digital ones. The professional expertise of Evgeny Barinov as the new General Director will significantly contribute to achieving the stated goals. Evgeny graduated with honors from the Moscow State Institute of International Relations (MGIMO), Faculty of International Business and Business Administration. He has extensive management experience and expertise in various sectors, including the pharmaceutical market. Evgeny Barinov has been working for Nanolek since 2013 and was directly involved in the company's development as a leader in the production of pediatric vaccines, holding the positions of a board member and deputy general director for finance and digital technologies at various time periods. For his contribution to the development of the biopharmaceutical industry, Evgeny Barinov received a letter of gratitude from the Ministry of Industry and Trade of the Russian Federation.
Evgeniy Barinov, General Director of Nanolek:
We will continue to strengthen our positions in the market of vaccines and specialized therapy drugs, as well as to develop the production site in the Kirov region. This year, we will complete work on launching a research and production center for pharmaceutical development, which will allow us to create our own active pharmaceutical substances. We will continue to build new capacities to scale up the production of recombinant, polysaccharide conjugate vaccines using yeast-based producer strains. The main goals of our company remain unchanged - the transfer of modern technologies, the creation of local competitive full-cycle vaccine production and, as a result, reducing dependence on external supplies. Our priority includes the national security and provision of the National Immunization Schedule.
